Summary of post-transplantation issues of study cohort
| Characteristic . | HLA-identical sibling . | Well-matched URD . | Mismatched URD . | Total* . |
|---|---|---|---|---|
| Prior grade of acute GVHD | ||||
| None | 84 (34) | 44 (19) | 56 (12) | 210 (19) |
| I or II | 102 (42) | 94 (41) | 190 (40) | 471 (42) |
| III or IV | 58 (24) | 91 (40) | 224 (48) | 436 (39) |
| Time from transplantation to cGVHD, months, median (range) | 4 (1-11) | 5 (2-11) | 4 (1-11) | 4 (1-11) |
| Onset of cGVHD | ||||
| Progressive | 121 (50) | 81 (35) | 233 (50) | 550 (49) |
| Interrupted | 35 (14) | 94 (41) | 154 (33) | 313 (28) |
| De novo | 84 (34) | 44 (19) | 56 (12) | 210 (19) |
| Missing | 4 (2) | 10 (4) | 27 (6) | 44 (4) |
| Karnofsky score at diagnosis of cGVHD | ||||
| < 80 | 37 (15) | 46 (20) | 147 (31) | 265 (24) |
| 80-100 | 194 (80) | 135 (59) | 257 (55) | 715 (64) |
| Unknown | 13 (5) | 48 (21) | 66 (14) | 137 (12) |
| Platelet count at diagnosis of cGVHD | ||||
| Median (range) | 162 (< 1-718) | 130 (6-441) | 115 (4-669) | 131 (< 1-718) |
| < 100 × 109/L | 49 (20) | 86 (38) | 183 (39) | 357 (32) |
| ≥ 100 × 109/L | 144 (59) | 131 (57) | 238 (51) | 602 (54) |
| Missing | 51 (21) | 12 (5) | 49 (10) | 158 (14) |
| Serum bilirubin at cGVHD | 1 (< 1-85) | 1 (< 1-15) | 1 (< 1-51) | 1 (< 1-85) |
| < 1 mg/dL | 113 (46) | 154 (67) | 292 (62) | 659 (59) |
| 1-2 mg/dL | 37 (15) | 41 (18) | 72 (15) | 166 (15) |
| > 2 mg/dL | 70 (29) | 15 (7) | 59 (13) | 175 (16) |
| Missing | 24 (10) | 19 (8) | 47 (10) | 117 (10) |
| Characteristic . | HLA-identical sibling . | Well-matched URD . | Mismatched URD . | Total* . |
|---|---|---|---|---|
| Prior grade of acute GVHD | ||||
| None | 84 (34) | 44 (19) | 56 (12) | 210 (19) |
| I or II | 102 (42) | 94 (41) | 190 (40) | 471 (42) |
| III or IV | 58 (24) | 91 (40) | 224 (48) | 436 (39) |
| Time from transplantation to cGVHD, months, median (range) | 4 (1-11) | 5 (2-11) | 4 (1-11) | 4 (1-11) |
| Onset of cGVHD | ||||
| Progressive | 121 (50) | 81 (35) | 233 (50) | 550 (49) |
| Interrupted | 35 (14) | 94 (41) | 154 (33) | 313 (28) |
| De novo | 84 (34) | 44 (19) | 56 (12) | 210 (19) |
| Missing | 4 (2) | 10 (4) | 27 (6) | 44 (4) |
| Karnofsky score at diagnosis of cGVHD | ||||
| < 80 | 37 (15) | 46 (20) | 147 (31) | 265 (24) |
| 80-100 | 194 (80) | 135 (59) | 257 (55) | 715 (64) |
| Unknown | 13 (5) | 48 (21) | 66 (14) | 137 (12) |
| Platelet count at diagnosis of cGVHD | ||||
| Median (range) | 162 (< 1-718) | 130 (6-441) | 115 (4-669) | 131 (< 1-718) |
| < 100 × 109/L | 49 (20) | 86 (38) | 183 (39) | 357 (32) |
| ≥ 100 × 109/L | 144 (59) | 131 (57) | 238 (51) | 602 (54) |
| Missing | 51 (21) | 12 (5) | 49 (10) | 158 (14) |
| Serum bilirubin at cGVHD | 1 (< 1-85) | 1 (< 1-15) | 1 (< 1-51) | 1 (< 1-85) |
| < 1 mg/dL | 113 (46) | 154 (67) | 292 (62) | 659 (59) |
| 1-2 mg/dL | 37 (15) | 41 (18) | 72 (15) | 166 (15) |
| > 2 mg/dL | 70 (29) | 15 (7) | 59 (13) | 175 (16) |
| Missing | 24 (10) | 19 (8) | 47 (10) | 117 (10) |
Other related (n = 86) and patients missing HLA data (n = 88) are not included in the donor columns. These groups are included in the Total column.